Biotech & AI Capital
Isomorphic Labs Raises $5B as Science Corp Secures $400M Series D
Demis Hassabis's AI drug-discovery spinout Isomorphic Labs closes a $5 billion Series C co-led by Sequoia and Greenoaks while Max Hodak's Science Corporation raises $400 million for its PRIMA retinal chip.

Your listening Queue & catch up
Add a story or build a catch-up queue to start listening.
Biotechnology and artificial intelligence companies announced $5.4 billion in combined late-stage venture financing on Tuesday as neural interface developer Science Corporation closed a $400 million Series D round and DeepMind spinout Isomorphic Labs secured $5 billion in Series C capital to advance AI-designed therapeutics into clinical trials.
Science Corporation Raises $400 Million Series D at $3.5 Billion Valuation for PRIMA Implant
Science Corporation, the medical technology company founded in 2021 by former Neuralink president Max Hodak, announced Tuesday that it has raised $400 million in Series D funding at a $3.5 billion valuation, according to TechCrunch — Artificial Intelligence. Investors participating in the round include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The company's lead commercial product, PRIMA, is a wearable and implantable retinal chip designed to help patients with age-related macular degeneration recover functional vision. Already approved in Europe and commercially available in Germany, PRIMA is now also being trialed for Stargardt disease, an inherited condition that causes progressive vision loss, as Hodak announced onstage at TechCrunch Disrupt. Science Corporation plans to use the $400 million financing to pursue U.S. regulatory clearance under the Food and Drug Administration's Humanitarian Device Exemption after demonstrating to the FDA that advanced bilateral macular degeneration meets rare-condition criteria. In parallel, Science is collaborating with Yale neurosurgery professor Murat Günel to design initial human trials of a bio-hybrid neural interface combining cultured neurons and silicon to address conditions such as Parkinson's disease.
Isomorphic Labs Secures $5 Billion Series C Co-Led by Greenoaks and Sequoia Capital
In computational drug discovery, Isomorphic Labs—spun out of Google's DeepMind in 2021—raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, as reported by TechCrunch — Artificial Intelligence. New investor Andreessen Horowitz joined existing backers including Alphabet's GV and CapitalG divisions, Thrive Capital, MGX, Temasek, and the U.K. Sovereign AI Fund.
The $5 billion financing follows a $2.1 billion Series B round completed in May and represents the company's first fundraise since founder and CEO Demis Hassabis—who shared the Nobel Prize in chemistry with John Jumper for the 3D protein-folding system AlphaFold—stepped down from leading DeepMind operationally to become DeepMind chairman and focus full-time on Isomorphic Labs. While Isomorphic did not disclose its valuation, Bloomberg reported earlier this month that the company had discussed raising capital at a $50 billion valuation. Having established research partnerships with Eli Lilly, Novartis, and Johnson & Johnson and generated positive preclinical results in oncology and immunology, Isomorphic Labs will deploy the new capital to move its AI-designed drug candidates into human clinical trials.
Sources
Comments (0)
No comments yet. Be the first to share a thought on this story.
Nominate a neighbor or local businessRequest a correctionContact the newsroom